switching from semiglutide to tirzepatide Semaglutide Switching from Semaglutide to Tirzepatide

Besides GLP-1RAs, the current meta-analysis included data from four placebo-controlled RCTs assessing the cardiovascular and cerebrovascular safety of the novel GIP/GLP-1 RA tirzepatide in T2DM patients

Thus, neurogenic coughers make as many as 60%

Only a small number of patients discontinued treatment due to adverse effects: one experienced severe constipation, another was concerned about media-reported risks of pancreatitis and thyroid cancer, and a third reported dizziness and bloating

Decreased appetite was reported by 11-31% among retatrutide-treated subjects (vs 9% placebo) in the obesity trial and by 10% (vs 2% placebo) in the diabetes trial [3,4]

Obesity-related comorbidities such as cardiovascular disease: as obesity and metabolic dysfunction worsen, effects of GIP/dual incretin therapies may address risk factors

Keros, 2024)